Procept Biorobotics Corp (PRCT)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.37B
Last updated: Nov 17, 2026 at 11:06 AM ET
Procept Biorobotics Corp (PRCT) Financials: Revenue, Profit and Cash Flow
Procept Biorobotics reported revenue of $308.05M for the fiscal year ended Dec 31, 2025, up 37.2% from the year before. That year, net income was -$95.57M with a net margin of -31.0%, operating cash flow was -$48.98M and free cash flow was -$58.34M. The quarter ended Sep 30, 2026 had revenue of $98.29M and net income of -$26.52M.
Revenue and Margins
The operating margin was -33.7% in the fiscal year ended Dec 2025, the highest of the 3 years shown with an operating margin. Over the 6 years to Dec 2025, revenue grew from $6.17M, a compound annual rate of 91.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $308.05M | +37.2% | 63.7% | -33.7% | -31.0% |
| Dec 2024 | $224.50M | +64.8% | 61.1% | -43.0% | -40.7% |
| Dec 2023 | $136.19M | +81.6% | 52.2% | -80.2% | -77.8% |
| Dec 2022 | $75.01M | +117.6% | 49.4% | -107.6% | -116.2% |
| Dec 2021 | $34.47M | +346.7% | 46.0% | -157.1% | -173.6% |
| Dec 2020 | $7.72M | +25.1% | -16.3% | -619.4% | -687.0% |
| Dec 2019 | $6.17M | N/A | -30.6% | -705.9% | -680.4% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $308.05M | $224.50M | $136.19M | $75.01M | $34.47M | $7.72M | $6.17M |
| Cost of revenue | $111.83M | $87.40M | $65.14M | $37.93M | $18.61M | $8.97M | $8.05M |
| Gross profit | $196.23M | $137.10M | $71.05M | $37.09M | $15.87M | -$1.25M | -$1.89M |
| Research and development | $71.28M | $62.30M | $48.45M | $28.98M | $18.99M | $16.27M | $13.15M |
| Operating income | -$103.86M | -$96.61M | -$109.17M | -$80.72M | -$54.16M | -$47.80M | -$43.55M |
| Net income | -$95.57M | -$91.41M | -$105.90M | -$87.15M | -$59.85M | -$53.02M | -$41.98M |
| EBITDA | -$85.41M | -$81.63M | -$98.02M | -$75.87M | -$50.72M | -$44.90M | -$39.76M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $98.29M | $94.50M | $83.13M | $76.38M | $83.33M | $79.18M | $69.16M | $68.24M | $58.37M | $53.35M | $44.54M | $43.58M |
| Gross profit | $65.15M | $62.38M | $53.95M | $46.31M | $54.01M | $51.75M | $44.16M | $43.67M | $36.91M | $31.48M | $25.03M | $21.25M |
| Operating income | -$27.38M | -$27.39M | -$32.61M | -$31.04M | -$23.19M | -$22.19M | -$27.44M | -$19.71M | -$22.43M | -$26.83M | -$27.65M | -$29.56M |
| Net income | -$26.52M | -$26.86M | -$31.64M | -$29.85M | -$21.41M | -$19.58M | -$24.74M | -$18.86M | -$20.97M | -$25.63M | -$25.96M | -$27.51M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded long-term debt of $51.62M by $234.89M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $508.08M | $534.02M | $404.72M | $309.33M | $337.02M | $125.97M | $61.99M |
| Current assets | $450.38M | $481.84M | $350.57M | $272.63M | $326.17M | $110.26M | $50.36M |
| Cash and equivalents | $286.50M | $333.73M | $257.22M | $221.86M | $304.32M | $100.13M | $42.02M |
| Total liabilities | $142.21M | $131.80M | $123.97M | $112.26M | $69.93M | $65.01M | $32.76M |
| Short-term debt | N/A | $1.91M | $1.68M | $2.13M | $2.10M | $4.55M | $3.07M |
| Long-term debt | $51.62M | $51.47M | $51.34M | $51.21M | $50.00M | $44.41M | $23.22M |
| Shareholder equity | $365.87M | $402.22M | $280.75M | $197.07M | $267.09M | -$182.89M | $29.23M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $473.76M | $479.35M | $487.06M | $508.08M | $511.54M | $513.05M | $519.38M | $534.02M | $374.14M | $374.35M | $382.90M | $404.72M |
| Total liabilities | $144.85M | $139.28M | $139.40M | $142.21M | $131.26M | $127.26M | $130.22M | $131.80M | $132.92M | $122.57M | $118.85M | $123.97M |
| Cash and equivalents | $218.37M | $227.91M | $245.64M | $286.50M | $294.28M | $302.72M | $316.21M | $333.73M | $196.76M | $214.09M | $225.58M | $257.22M |
| Shareholder equity | $328.91M | $340.07M | $347.67M | $365.87M | $380.28M | $385.80M | $389.16M | $402.22M | $241.22M | $251.78M | $264.05M | $280.75M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$48.98M | -$99.21M | -$108.00M | -$80.38M | -$57.33M | -$48.34M | -$43.82M |
| Capital expenditures | $9.36M | $4.41M | $25.21M | $2.65M | $592.00K | $233.00K | $7.61M |
| Free cash flow | -$58.34M | -$103.62M | -$133.21M | -$83.03M | -$57.93M | -$48.58M | -$51.43M |
| Investing cash flow | -$9.36M | -$4.41M | -$25.21M | -$2.65M | -$592.00K | -$233.00K | $43.15M |
| Financing cash flow | $11.19M | $180.13M | $167.79M | $3.61M | $262.12M | $106.77M | $26.53M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.98M | -$19.25M | -$38.13M | -$10.33M | -$6.63M | -$15.04M | -$16.98M | -$32.39M | -$18.80M | -$15.74M | -$32.29M | -$24.79M |
| Capital expenditures | $667.00K | $2.95M | $2.91M | $1.85M | $2.87M | $2.80M | $1.84M | $1.17M | $246.00K | $1.04M | $1.95M | $8.71M |
| Free cash flow | -$9.65M | -$22.20M | -$41.04M | -$12.18M | -$9.50M | -$17.84M | -$18.82M | -$33.56M | -$19.05M | -$16.78M | -$34.23M | -$33.51M |
Frequently Asked Questions About PRCT
What is Procept Biorobotics' annual revenue?
Procept Biorobotics reported revenue of $308.05M for the fiscal year ended Dec 31, 2025.
How fast is Procept Biorobotics' revenue growing?
Revenue was up 37.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 60.1%.
Is Procept Biorobotics profitable?
No. Procept Biorobotics reported net income of -$95.57M for the fiscal year ended Dec 31, 2025, with a net margin of -31.0%.
How much free cash flow does PRCT generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$48.98M minus capital expenditures of $9.36M produced free cash flow of -$58.34M.
How much debt does Procept Biorobotics have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $51.62M and cash and equivalents of $286.50M.
PRCT pages: Overview, Earnings, Forecast, Financials, Competitors